This Week on Drug Topics: May 10 to May 14
Here’s a preview of the featured content to watch for this week on Drug Topics®.
Coronavirus Research News
With an estimated 260 million COVID-19 vaccine doses administered and 578,000 COVID-19–associated deaths in the US as of this article’s press time, keeping up with pandemic news is more important than ever.
In vaccine-related news, the FDA is expected to soon authorize Pfizer-BioNTech’s COVID-19 vaccine for children aged 12 to 15 years. The vaccine is currently authorized only for individuals 16 years of age and older. The decision could come as early as this week.
Check back to Drug Topics® to stay informed on the latest coronavirus-related news and research.
Read more coronavirus-related news.
Drug Topics® Journal, May 2021 Digital Edition
The May 2021 digital edition of Drug Topics Journal is now available on DrugTopics.com. In this issue, Drug Topics® covers the latest in diabetes, vaccines, health systems, and more, and our cover story highlights the emerging roles in mental health care for pharmacists.
A Global Comparison of Drug Pricing
Variations in prescription drug prices can be due to a variety of reasons. In an upcoming article on Drug Topics®, Zakieh Abuelkhair, RPh, MPBA Candidate, breaks down what influences drug prices and the differences between the United States and United Arab Emirates.
Check back this week to read the article on drugtopics.com.
Total Pharmacy®: Pharmacy owner discusses community initiatives
In an upcoming interview, Dan Singh, owner of Dan’s Wellness Pharmacy in Stafford, Virginia, discusses how his store is giving back to the community amid the COVID-19 pandemic.
Visit totalpharmacy.com for more.
In Case You Missed It: FDA OKs Dapagliflozin for Chronic Kidney Disease
Last week, the FDA approved dapagliflozin (Farxiga; AstraZeneca) for use in patients with chronic kidney disease (CKD) at risk of progression.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
